Ramatroban

Jump to: navigation, search
Ramatroban
Ramatroban.svg
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H21FN2O4S
Molar mass416.46 g/mol
3D model (JSmol)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Ramatroban (INN) is a thromboxane receptor antagonist indicated for the treatment of coronary artery disease.[1] It has also been used for the treatment of asthma.[2]

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the tradename Baynas.

References

  1. Fiedler VB, Seuter F, Perzborn E (1990). "Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease". Stroke. 21 (12 Suppl): IV149–51. PMID 2260140. Unknown parameter |month= ignored (help)
  2. Endo S, Akiyama K (1996). "[Thromboxane A2 receptor antagonist in asthma therapy]". Nippon Rinsho (in Japanese). 54 (11): 3045–8. PMID 8950952. Unknown parameter |month= ignored (help)



Linked-in.jpg